R. Das

Macrophage migration inhibitory factor regulates innate γδ T‐cell responses via IL‐17 expression

L. Leng, R. Bucala, P. Tilstam, 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Raghavendra C Kamath, A. T. Adebanjo, Jennifer L. Small, 2020, Lancet.

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

J. Schlom, C. Van Waes, J. Friedman, 2019, JCI insight.

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

C. Miller, R. Jain, Angela Tam, 2017, Science Translational Medicine.

Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

R. Jain, Angela Tam, R. Schlegel, 2017 .

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Angela Tam, Manway Liu, J. Baselga, 2015, Cancer cell.

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

W. Sellers, J. Gu, C. Arteaga, 2013, Cancer research.

Lymphotoxin‐β receptor‐NIK signaling induces alternative RELB/NF‐κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer

C. Van Waes, Zhong Chen, Anthony D. Saleh, 2018, Molecular carcinogenesis.

Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer

Steven J. M. Jones, Thomas M. Harris, Ludmila V. Danilova, 2019, Clinical Cancer Research.

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth

J. Lehár, Anupama Reddy, P. Finan, 2012, PloS one.

Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation.

Dongshu Chen, Q. Sheng, S. Ettenberg, 2012 .